Icalcaprant[1] (developmental code name CVL-354) is a κ-opioid receptor (KOR) antagonist which is under development for the treatment of major depressive disorder and substance-related disorders.[2][3] It is taken by mouth.[2]
It acts as a selective antagonist of the KOR.[2][3] The drug is also more weakly an antagonist of the μ-opioid receptor (MOR), with about 31-fold lower affinity and 27-fold lower inhibitory potency at the MOR relative to the KOR.[3]
It was originated by Pfizer and is under development by Cerevel Therapeutics (a subsidiary of AbbVie).[2][4] As of September 2022, icalcaprant is in phase 1 clinical trials for major depressive disorder and is in the preclincal stage of development for substance-related disorders.[2]
See also
- κ-Opioid receptor § Antagonists
- List of investigational antidepressants
- List of investigational bipolar disorder drugs
- List of investigational substance-related disorder drugs
- Aticaprant and navacaprant
References
- ^ “Icalcaprant (CVL-354)”. AbbVie. Retrieved 2024-08-15.
- ^ a b c d e “CVL 354 – Cerevel therapeutics”. Adis Insight. Springer Nature Switzerland AG.
- ^ a b c “ACNP 61st Annual Meeting: Poster Abstracts P271-P540”. Neuropsychopharmacology. 47 (Suppl 1): 220–370. December 2022. doi:10.1038/s41386-022-01485-0. eISSN 1740-634X. PMC 9714399. PMID 36456694.
- ^ “AbbVie Completes Acquisition of Cerevel Therapeutics”. AbbVie News Center. Retrieved 2025-05-07.